United States Patent 5,629,021: Scope, Claim Boundaries, and Landscape

United States Patent 5,629,021 covers micellar nanoparticle compositions and structure-based parameters (size, phase components, initiator chemistry, and stabilizer selection) aimed at forming oil-in-water micellar systems that are dispersible and filterable, including drug-loaded embodiments with estradiol. The claim set is drafted to combine (i) defined physical characteristics and (ii) a narrow but enabling formulation recipe: oil + selected stabilizers + an alcohol-based initiator, hydrated with a specified aqueous system.

This analysis parses claim scope, identifies key claim “pressure points” for design-around, and maps likely competitive overlap areas in micellar drug delivery. It also surfaces claim dependencies that tighten coverage around alcohol type, ethanol concentration, payload location, and size-driven filter passage.

What is the core claim scope of US 5,629,021?

Independent claim 1 sets the composition-plus-structure frame

Claim 1 is the coverage anchor. It defines:

Object: “A micellar nanoparticle”
Size: “between about 25 and 1000 nm”
Composition:
- Lipophilic phase includes:
- an oil
- a stabilizer
- an alcohol-based initiator
- Hydrated with a suitable aqueous solution
Stabilizer restriction (key limiter): stabilizer selected from:
- Tween 60
- Tween 80
- nonylphenol polyethylene glycol ethers
- mixtures of the above

Functional/structural qualifiers included via later claims: dispersibility in water (claim 11), filter passage through 0.2 mm filter (claim 12), and payload location (claims 7-9). But claim 1 itself already limits the formulation architecture.

Implication for freedom-to-operate (FTO): Any accused product must form micellar nanoparticles with (a) size in the 25-1000 nm range and (b) a lipophilic phase that uses an alcohol-based initiator and one of the recited stabilizers. If either stabilizer selection or the presence/nature of the initiator is outside the specified framing, claim 1 coverage narrows sharply.

Claims 2–3 narrow the alcohol initiator

Claim 2 narrows the initiator:

Alcohol-based initiator is selected from methanol, ethanol, and mixtures.

Claim 3 adds an ethanol concentration constraint:

initiator is alcoholic materials containing 50% or higher ethanol, methanol, and mixtures.

Implication: Coverage tightens toward formulations where the initiator alcohol is ethanol (at or above 50%) or methanol. A system relying on isopropanol, propylene glycol, glycerol, or other alcohols not within the claim-recited list can sit outside the scope of dependent claims, though claim 1 does not explicitly list ethanol/methanol for initiator. Still, if the patent examiner or litigant construes “alcohol-based initiator” as requiring one of the claimed alcohols, the dependent claims inform meaning.

Claim 4 narrows the oil component

Claim 4 limits oil selection to:

vegetable oils
nut oils
fish oils
lard oil
mineral oils
squalane
tricaprylin
mixtures

Implication: If a competitor uses oils outside this list (for example, certain synthetic esters not falling into these buckets), it may avoid claim coverage depending on how “selected from the group consisting of” is construed. The breadth is still substantial because many common lipids fall into “vegetable,” “mineral oil,” “squalane,” and “tricaprylin.”

Claims 5–6 narrow hydration medium

Claim 5: aqueous solution comprises a “physiologically compatible solution.”

Claim 6: aqueous solution is selected from:

water
phosphate buffered saline

Implication: Systems using non-physiological media or buffers other than PBS may fall outside claims 5–6, but claim 1 already says “suitable aqueous solution,” which is broader than the dependent selection. Claim 6 becomes a tighter fallback feature.

Claims 7–9 add payload localization

Claim 7: active material dissolved or suspended in the aqueous phase.
Claim 8: active material dissolved or suspended in the oil (lipophilic) phase.
Claim 9: initiator has an active material dissolved or suspended therein.

Claim 9 is unusual: it claims an active distributed into the initiator portion, not just oil or aqueous phase. That creates another design-around axis: load the drug into oil or aqueous and avoid loading into the initiator itself.

Claim 10 adds a specific payload: estradiol

Claim 10: active material comprises estradiol.

Implication: Products without estradiol (or not containing estradiol as the active) can avoid claim 10 even if they practice other structural features.

Claims 11–12 add dispersibility and filterability

Claim 11: micellar nanoparticle is “dispersible in aqueous solution.”

Claim 12: “diameter allows passage through a 0.2 mm filter.”

Implication: Claim 12 is a paradoxical-looking unit mismatch: 0.2 mm equals 200 microns, while claim 1 caps micellar diameter at 1000 nm (0.001 mm). On its face, nanoparticles in the 25–1000 nm range will always pass a 200-micron filter. Litigants usually treat this as a supportive limitation that is easy to satisfy if claim 1 size is met. Still, it ties to physical testability in prosecution/litigation.

How do the dependent claims affect infringement risk?

Two-stage scope: claim 1 is the gate; dependent claims add fallback feature sets

If a product matches claim 1 components and size, infringement can be assessed directly under independent claim 1.
If key elements of claim 1 are missed, dependent claims matter less because they are narrower. But the dependent claims reveal what the patent intended to differentiate: stabilizer types, ethanol/methanol initiator, and payload placement.

Key tighteners from dependencies

Initiator type (claims 2–3): ethanol/methanol and potentially ethanol concentration >= 50%
Oil selection (claim 4): limited to enumerated oil categories plus mixtures
Buffer medium selection (claim 6): water or PBS
Payload location (claims 7–9): aqueous, oil, or initiator-loading
Drug identity (claim 10): estradiol
Physical property marketing (claims 11–12): dispersible and 0.2 mm filter passage

What elements are most vulnerable for design-around?

1) Stabilizer selection is the strongest chemical limiter in claim 1

Claim 1 restricts stabilizer to:

Tween 60
Tween 80
nonylphenol polyethylene glycol ethers
mixtures

A competitor can design around by using alternative nonionic surfactants or polymer stabilizers not falling into these groups, even if oil and alcohol initiator are similar and size is within range.

Examples of potential avoidance strategies (conceptual):

Switch from Tween 80/Tween 60 to a different surfactant system (e.g., other polysorbates, poloxamers, bile salts, or lecithin-based emulsifiers) unless one of those is treated as falling into the enumerated categories.
Replace nonylphenol polyethylene glycol ethers with other alkylphenol ethoxylates that do not match the “nonylphenol polyethylene glycol ethers” wording (the literal language suggests nonylphenol specifically).

2) Alcohol initiator composition (claims 2–3) narrows further

Even if claim 1’s “alcohol-based initiator” is argued broadly, dependent claims expressly list ethanol and methanol (and ethanol >= 50% in claim 3). If a competitor uses a different alcohol initiator, it reduces alignment with claim 2 and claim 3.

3) Payload location (claims 7–9) can be used to avoid narrower coverage

If a competitor uses an active drug but confines it to:

the oil phase (claim 8) or
the aqueous phase (claim 7)

they avoid claim 9 only if they do not also place active in the initiator. Conversely, if the patent strategy is to cover “initiator-loaded” actives, a competitor can load the active into oil or aqueous and avoid initiator loading.

4) Estradiol identity (claim 10) is a straightforward avoidance lever

If the formulation uses no estradiol, claim 10 is not implicated.

What is the likely patent landscape position for US 5,629,021?

Landscape category: micellar nanoparticle drug delivery with defined excipient selection

The claim architecture places US 5,629,021 within a larger field of micellar and nano-micellar delivery systems. Many patents in this area claim:

amphiphiles/surfactants to form micelles
solvent/alcohol or cosolvent systems to solubilize actives
drug loading into micelles
size/dispersibility and sometimes filterability metrics
buffer-compatible delivery conditions

What US 5,629,021 adds is specificity:

stabilizer recitation (Tween 60, Tween 80, nonylphenol polyethylene glycol ethers)
alcohol initiator recitation (ethanol/methanol, with ethanol >= 50% in a dependent claim)
oil list including squalane and tricaprylin
payload location including initiator loading
estradiol as a concrete active example

Where competitors typically cluster

Given this claim language, the most likely overlap occurs among products or patents that:

use Tween 80 or Tween 60 and/or nonylphenol polyethylene glycol ethers
use ethanol-rich or methanol-based initiators to form oil-in-water micellar systems
formulate hydrophobic actives (including steroids like estradiol)
use aqueous buffers like water or PBS

Where competitors can avoid overlap

Overlap drops substantially when any of these are changed beyond claim recitations:

stabilizer swaps away from the enumerated set
initiator uses other alcohols or non-alcohol cosolvent systems
drug-loading avoids initiator-phase loading and/or uses different actives
formulation targets size outside 25–1000 nm (for example, classic macroemulsions)

Claim-by-claim scope map (practical reading for infringement analysis)

Claim	Additional limitation beyond prior claim(s)	Scope impact (who it includes)
1	25–1000 nm micellar nanoparticles; lipophilic phase = oil + stabilizer + alcohol-based initiator; hydrated with suitable aqueous solution; stabilizer = Tween 60 / Tween 80 / nonylphenol PEG ethers	Broadest coverage; sets excipient and size boundaries
2	Initiator = methanol, ethanol, or mixtures	Narrows initiator chemistry
3	Initiator includes alcoholic materials with 50%+ ethanol; also methanol; mixtures	Narrows toward ethanol-heavy initiator compositions
4	Oil = vegetable/nut/fish/lard/mineral oils, squalane, tricaprylin, mixtures	Limits lipophilic phase oil identity
5	Aqueous solution = physiologically compatible solution	Broad soft restriction (depends on construction)
6	Aqueous solution = water or phosphate buffered saline	Narrow buffer selection
7	Active dissolved/suspended in aqueous phase	Payload location: hydrophilic distribution
8	Active dissolved/suspended in oil	Payload location: lipophilic distribution
9	Active dissolved/suspended in initiator	Payload location: initiator compartment
10	Active = estradiol	Narrows payload identity
11	Micelles dispersible in aqueous solution	Practical property; usually met if hydrated system forms micelles
12	Diameter allows passage through 0.2 mm filter	Likely redundant given 25–1000 nm size; adds a test-based feature

How does the claim language affect measurement and proof?

Size and micellar definition

Claim 1’s “diameter between about 25 and 1000 nm” suggests that proof will rely on sizing techniques (light scattering, electron microscopy, dynamic light scattering).
The “micellar nanoparticle” label can invite disputes about whether the system is truly micellar versus nanoemulsion or mixed micelle/emulsion. Still, the claim focuses on a defined recipe rather than only a morphological descriptor.

Filter passage

Claim 12 ties a functional test to diameter. Given the upper limit is 1000 nm (1 micrometer) and 0.2 mm is 200 micrometers, a micellar system within claim 1 will pass. This claim appears to reinforce practical dispersibility rather than restrict beyond claim 1.

Key Takeaways

US 5,629,021 is built around a tight excipient triad: oil + enumerated stabilizers (Tween 60/Tween 80/nonylphenol PEG ethers) + an alcohol-based initiator, forming 25–1000 nm micellar nanoparticles.
The stabilizer list is the highest-value design-around lever because it is an explicit group restriction in claim 1.
Ethanol/methanol initiator limits fall into dependent claims (2–3), but they shape how the “alcohol-based initiator” will be interpreted.
Payload coverage splits by compartment (aqueous phase vs oil vs initiator), with estradiol explicitly singled out in claim 10.
Buffer choice (water or PBS) is narrowed in claim 6, while 0.2 mm filter passage appears largely confirmatory given the nanoparticle size range.

FAQs

Is claim 1 limited to estradiol?
No. Estradiol is only specified in claim 10. Claim 1 covers micellar nanoparticles with an unspecified active material dissolved or suspended (addressed structurally by claims 7–9 rather than identity).
What is the strongest literal limitation in claim 1?
The stabilizer is restricted to Tween 60, Tween 80, nonylphenol polyethylene glycol ethers, or mixtures.
Can a formulation using different surfactants still infringe claim 1?
If the stabilizer is not one of the enumerated stabilizers (or mixtures that still include them), claim 1 is not met as written.
Does claim 12 restrict particle size beyond claim 1?
Practically, no. Claim 1 limits diameter to 25–1000 nm, which will pass a 0.2 mm filter. Claim 12 mainly reinforces testability rather than adding a tighter size ceiling.
What does claim 9 add compared with claims 7 and 8?
Claim 9 requires the active material to be dissolved or suspended in the initiator portion, not only in the aqueous or oil phases.

References

[1] United States Patent 5,629,021. (Claims provided in user prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	4970996	⤷ Start Trial
Australia	711744	⤷ Start Trial
Brazil	9606996	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,629,021

Summary for Patent: 5,629,021